Home / Transcripts / FutureFuel Corp. (FF) · November 10, 2026

FutureFuel Corp. (FF) Earnings Call Transcript

November 10, 2026

New York Stock Exchange US Energy Oil, Gas and Consumable Fuels earnings 31 min

Earnings Call Speaker Segments

Rose Sparks executive
#1

Good morning, everyone, and thank you for joining us on this call to discuss FutureFuel's results for the third quarter of 2026. Leading today's discussion is Roeland Polet, our Chairman and CEO, and I'm Rose Sparks, the company's Chief Financial Officer. We issued a press release yesterday following the close of U.S. trading that detailed our operational and financial performance for the third quarter. You can find that release publicly in the Investor Relations section of our corporate website at www.futurefuelcorporation.com. Please be aware that management's remarks and our answers to your questions today may contain forward-looking statements, which are inherently uncertain and beyond the company's control. Although these forward-looking statements are based on what management currently expects and believes, actual results might turn out materially different. If you want to understand some of the factors that might lead actual results to differ, we point you to the Risk Factors section in the latest reports we have filed with the SEC. In addition, reconciliations for every historical non-GAAP financial measure we discuss on this call are available in the press release that went out yesterday. Roeland Polet will start today's call with prepared remarks giving a business update, and after that I will review how we performed financially in the third quarter. Once those prepared remarks are finished, we will open the line for questions. I'll now hand the call to Roeland.

Roeland Polet executive
#2

Thank you, Rose, and good morning to everyone who's with us on today's call. Our third quarter results told 2 distinct operating stories. On one side, we delivered an exceptional operating quarter in our biofuel segment, with capacity utilization climbing to its highest level in over 2 years and surpassing 80%. Biodiesel demand is still strong as we leave the third quarter, and we anticipate it will accelerate even more as we head into 2027. Recent regulatory shifts in renewable fuels markets will further shrink the RIN equivalency advantage that renewable diesel producers previously held and strengthen the competitive standing of biodiesel producers, ourselves included. On that same topic, by early November we had secured orders for over 90% of the biodiesel output we have available in the fourth quarter, which is considerably ahead of our prior expectations. That unusually clear view of our business gives us a firm picture of what 2027 may hold for our biofuel segment. Even so, although the biofuel segment saw higher utilization, greater sales volumes, and improved price capture, the combination of elevated feedstock costs and losses on derivatives resulted in a gross loss for that segment during the period. It is worth pointing out, however, that we anticipate selling $1.5 million of RINs produced from third quarter biodiesel output and recovering $2.3 million in derivative losses associated with matching sales of physical inventory in the fourth quarter. Within our main Chemicals business, sales volume fell 27% year over year because dedicated process units that serve two distinct customers underwent prolonged maintenance. For customer A, we moved up a scheduled turnaround on a dedicated production unit after that customer said it would briefly halt its usual ordering rhythm to bring inventory levels back into balance. Notably, customer A has signaled that it plans to return to a normal ordering rhythm in November, and the turnaround work it had scheduled is now finished. Also worth noting is that customer A has pledged $41 million in customer-funded growth capital investment at Batesville across 2026 through 2028, as they look to take advantage of the flexibility our site provides; they are a strong partner who greatly values what we offer, and their commitment to the investments underway at Batesville remains very high. That said, the turnaround at the customer production unit, along with a separate turnaround at customer B, another long-time customer, held back throughput rates in the Chemicals segment during the period. Reduced production rates in the Chemicals segment weighed on operating leverage in the third quarter, which put pressure on profitability. Taken as a whole, those developments cut adjusted EBITDA for the third quarter by roughly $4.3 million. The key point is that while the disruption was temporary, we kept our focus on the things we could control. Production units came in on plan, expenses stayed in check, and our growth initiatives progressed on schedule. We maintained the same operating cadence throughout, even while adjusting to near-term headwinds that have now been resolved. With both turnarounds at our chemical business now complete and no significant scheduled maintenance ahead through Q1 of 2027, we are positioned for a strong close to 2026 and a solid start to the coming year. Before handing things over to Rose for a brief review of our Q3 results, I wanted to update you on the significant strides we're making against our strategic value creation priorities. At FutureFuel, value creation stands on three pillars — commercial growth, operational excellence, and returns-driven capital allocation. Concretely, our road map for creating value focuses on accelerating quote-to-order conversion across the chemicals opportunities pipeline, increasing production volumes with existing customers as we deepen our integration into their supply chains, and seizing reshoring opportunities as European chemical producers increasingly weigh the advantages of our cost-advantaged U.S. manufacturing footprint, where natural gas costs remain substantially below those in Europe. What this also involves is turning waste streams into products with greater added value, which raises our average selling prices and margins, and getting our biodiesels business back to ideal production levels as market conditions keep getting better — in line with what the third quarter showed us. The key point is that these priorities aren't our only focus. We're carrying them out at this very moment. Beginning with the commercial side: during the third quarter, we built a new relationship with a major European chemicals company that is moving production back to the United States so it can serve its customers better and take advantage of the cost benefits of manufacturing in the U.S. European natural gas prices are still multiple times above U.S. levels, and that puts European chemicals makers at a major structural cost disadvantage, making it harder and harder to justify keeping production going as operating costs broadly climb. For chemical companies looking to move manufacturing back from abroad into the United States, FutureFuel provides a turnkey, cost-competitive domestic option, drawing on our existing infrastructure, specialized technical know-how and production capacity that can scale. With this customer, we anticipate starting initial batch output during the first quarter of 2027 and hitting full production rates by mid-2027. Operationally, we recently kicked off the productivity initiative aimed at boosting efficiency and optimizing our cost structure. With help from outside advisers, we've found several near-term chances to boost efficiency at Batesville, among them upgrading waste streams into products with more added value. Glycerin — the waste stream from our biodiesel operation — can be refined and sold at about three times the per-gallon value of the unrefined glycerin coming up the biodiesel stream, at minimal incremental cost to us, which works out to a potential opportunity of $5 million to $10 million for us starting in 2027. Given an inflationary environment, we're also continuing to pass through higher energy, material and labor costs under the customer agreements that give us cost indexing. You'll hear more in the coming quarters about the cost actions being taken in our business. It's early days, but the opportunities are significant. We haven't changed how we deploy capital; the focus is still on investments that are disciplined, driven by returns, and built to grow shareholder value over the long term. Customer-funded projects at Batesville remain at the top of the list, together with the working capital needed for feedstock buying, while we preserve room for capital-return priorities. Briefly on liquidity: getting our cash balance back up to $50 million within the coming year is a major focus for us. The working capital tied to feedstock purchases continues to run high, and that has pulled heavily on the liquidity we have available. That doesn't catch us off guard, and we're ready for it, but it also means we plan to delay any move on buying back shares and/or increasing the cash dividend until the balance sheet is stronger, which we are fully committed to doing. A final point on capital investments driven by customers. Customer-funded growth capital totaled $16.1 million this year, roughly 50% of our total CapEx. From 2028 through 2029, we presently anticipate customers putting an extra $15 million to $20 million into our Batesville site. As we've noted previously, these third-party investments don't just boost our value to customers—they strengthen the relationship, forging a partnership with unusually high synergy. We believe the worth of our company is quite evident, since we are the sole U.S.-based specialty chemicals platform that brings together decades of technical know-how, sophisticated chemical synthesis abilities, and a cost-competitive, integrated domestic production base. Customers don't just treat us as a vendor—they see us as an extension of their own manufacturing operations, which lets them lower capital intensity while upholding strict quality standards and dependable large-scale output. Building on that, our focus will be on creating a leaner and more profitable operation that generates stronger operating leverage as time goes on. Winning new customers and expanding wallet share among existing partners will fuel the opportunity, though rationalizing costs will be just as essential. This is a thrilling moment for the company, and we’re grateful for the collaboration of our partners, customers and shareholders as we enter a fresh chapter of value creation. With that said, I’ll now pass the call to Rose for her prepared remarks.

Rose Sparks executive
#3

Thanks, Roeland, and good morning everyone joining us. I'll give you a high-level look at how we performed financially in the third quarter today, along with a review of our balance sheet and liquidity position as of quarter end. Revenue for the third quarter totaled $104.7 million, which is an increase of 361.3% from $22.7 million a year earlier. That $82 million gain was made up of $36.3 million coming from volume and product mix, plus $45.7 million from pricing, mostly within the Biofuel segment. We had a total gross loss of $5.4 million in the third quarter of 2026, compared with a gross loss of $6.5 million in the third quarter of 2025. Results for the third quarter include $8.7 million in net derivative losses, made up of $8.3 million of realized losses and $0.4 million of unrealized losses. Within the realized derivative losses, $2.3 million relates to physical inventory that has not yet been sold, and we expect that amount to be recovered in the fourth quarter. As of September 30, the company held roughly $0.7 million of internally generated RINs valued at $1.5 million for delivery during the fourth quarter. The associated sales benefit was excluded from third quarter results and will be recognized once those RINs are transferred. The company posted a net loss of $8.4 million in the third quarter of 2026, versus a net loss of $9.2 million in the third quarter of 2025. Adjusted EBITDA came in as a loss of $4.9 million during the third quarter of 2026, compared with a $5.3 million loss in the third quarter of 2025. Now moving to the Chemicals segment. Segment revenue reached $16.9 million in the third quarter of 2026, an 8.6% rise from $15.6 million in the third quarter of 2025. That increase came from contributions of higher volume and product mix. Custom chemical revenue was $13.3 million, a decline of 8% from $14.5 million a year ago, mainly because of delayed shipments as a large customer rebalanced inventory, along with production downtime for a second customer during an extended scheduled turnaround. Performance Chemical revenue was $3.6 million, up 223% from $1.1 million a year ago, largely driven by higher volumes from a new customer that started production in the fourth quarter of 2025, as well as higher glycerin sales. Gross profit was $4.4 million, compared to a loss of $4.1 million in the third quarter of 2025. The improvement came from higher sales volumes in the energy market and lower indirect fixed cost absorption from operating infrastructure with strong biofuel volumes, partly offset by the customer disruptions Roeland described earlier. Business momentum in the Chemicals segment kept building despite temporary volume disruptions in the third quarter, as shown by recent customer wins and a robust project pipeline. Chemical segment capacity utilization was 32% in the third quarter of 2026, compared to 55% in the year ago period. After recent capacity expansions and debottlenecking activities, the company expects fourth quarter Chemical segment level capacity utilization to be above prior year levels. For the Biofuel segment, revenue was $87.8 million in the third quarter of 2026, compared to $7.1 million in the same period last year. Higher regulatory clarity, record renewable volume obligation levels, and solid operational execution in the quarter all contributed to that increase. In the Biofuel segment, the third quarter showed a gross loss of $9.8 million, versus a gross loss of $2.4 million in the same period a year earlier. As Roeland mentioned, much higher sales volumes and better pricing realization were outweighed by elevated input costs along with higher plant operating and fixed manufacturing expenses, compared with shutdown holding costs in the prior year period. Within the third quarter gross loss were hedging losses of $2.3 million, which should be offset once the underlying physical commodity positions are sold in future periods, and $1.5 million of RIN inventory that will benefit Q4 when sold. On a year-to-date basis, market conditions in the biofuel segment have improved considerably, helped by better regulatory clarity regarding domestic renewable fuel blending obligations, tax incentives, and how domestically produced biofuels are treated. Biofuels capacity utilization rose to 83% in the third quarter from 56% in the second quarter, and sales volumes should stay high as we enter the fourth quarter and move into 2027. Although demand conditions should remain strong in the near to medium term, input costs for soy oil and other raw materials are still elevated, which should weigh on Biofuel segment gross profit per gallon sold in the near term. Moving to cash flow, the balance sheet, and liquidity. At September 30, 2026, total cash and equivalents stood at $21.3 million, lower than $34.3 million at June 30, 2026, and the company had a $35 million revolving credit facility with no borrowings outstanding. The reduction in total cash during the third quarter of 2026 reflected the operating loss in the third quarter of 2026, greater working capital requirements, and capital expenditures made to support growth. Net cash used in operations came to $10.3 million in the third quarter, compared with a use of $1.1 million in the prior year period. Capital expenditures totaled $3.3 million in the third quarter, including $0.6 million and $2.7 million tied to maintenance and discretionary programs, respectively; during the first 9 months of 2026, about 74% of the $2.7 million in discretionary capital expenditures were customer-funded investments linked to capacity expansions and new customer programs. That wraps up our prepared remarks. Operator, we're now ready for the question-and-answer portion of our call.

Jason Tilchen analyst
#4

Before we begin, I want to explore the reshoring opportunity in more depth, plus that new partnership you brought up involving a major European chemicals client. Could you give us additional context on the way that relationship came together, and also the approximate timing and scale of what this customer will contribute in 2027? Then, on a wider level, how do you see additional reshoring possibilities acting as a kind of proof of concept, if you will?

Roeland Polet executive
#5

Especially during the past year, we've noticed a substantial rise in questions coming from European chemical manufacturers that supply the U.S. The European manufacturing angle is where this chance originated. The customer came to us aware that we can handle sophisticated chemistries at our Batesville operation. Right now they bring the product in from Europe, but doing that no longer makes economic sense, so they picked us to set up a production line at the Batesville site that will take over that output. Inquiries of this kind are arriving in growing numbers. The pace has risen sharply, and the potential here may actually exceed what we're seeing from reshoring out of China and India. We expect more customers beyond this one will pursue reshoring, so while this does affect our bottom line meaningfully—or materially—the larger effect will come from additional reshoring opportunities headed toward the United States.

Jason Tilchen analyst
#6

All right, that's very useful. You brought up the glycerin opportunity in the prepared remarks. I was just wondering whether you could speak to some of the operational milestones, and also the commercial ones, for you to seize this opportunity, plus what the CapEx might roughly look like and how fast you can get to that run rate of $5 million to $10 million of incremental profit that was mentioned.

Roeland Polet executive
#7

Yes. In full transparency, we have refined a small quantity of glycerin previously; there's a modest — a very modest — amount of CapEx going into this so we can convert more equipment to turn crude glycerin into refined glycerin. So it's under $1 million in CapEx to build this additional capacity; and the real driver here is the margin expansion we've observed in refined glycerin. Refined glycerin has therefore seen considerable upside in market pricing, to the point that for us this became an almost no-brainer project to go and execute. And we'll be up and running by, I'd say, the end of Q4, and we'll be running right through 2027.

Jason Tilchen analyst
#8

Great. That's really useful. And if I could squeeze in one final question for myself. Last week's midterm results brought what looked like a fairly substantial change in the political wins. I'm curious whether FutureFuel has any broader perspective on how that result might affect the business, whether directly or indirectly, and how the regulatory environment could develop? Anything along those lines would be really useful.

Roeland Polet executive
#9

Yes. We honestly don't perceive a particularly large shift in the way that will impact our business, right? So the — let's turn to our biofuels business. So our biofuels business genuinely has backing from the Republican party as well as the Democratic party. This covers farmers — really the core of America. And both parties have been quite supportive of that economic segment. So we don't expect any significant shift. As you know, we've got regulatory certainty through the start of 2030 — actually through the close of 2029. There's no reason we can see for that to stop after that point; and incidentally, that's what's been driving the gains in our biofuels business, correct? For Q4 we are essentially — nearly fully booked. We've had a strong increase there, and that's really thanks to that certainty. In our view, no matter which party holds office or has control, that clarity isn't going anywhere.

Jeff Van Sinderen analyst
#10

I'd like to talk a bit about those higher input costs. Could you take us through how you're offsetting them, especially as we think about metrics getting better in Q4?

Roeland Polet executive
#11

Sure, I'll begin, and Rose will definitely chime in too. On the elevated side — we view the biofuels business as a spread business, correct? So we focus on — no matter what the input and the sales price are, we aim to generate a particular spread; and that spread has actually come in above what we anticipated at the start of the year. It's been quite healthy. But given that diesel prices have been elevated, very elevated, the input prices have risen as well. So bean oil, which is one of our main inputs, has been at all-time highs. And many of the other fats and greases we use to produce biodiesel have also been at all-time highs. Now I'll say that we've begun — we have begun to see some moderation in these inputs, and especially the inputs that — maybe to take a step back, right? So FutureFuel is in a very unique position to run a multitude of inputs. Because we're set up as a chemical plant that makes biodiesel, we can take a wide variety of inputs. And every input was high. What we're beginning to see now is that — a larger group of inputs is starting to ease in price, including bean oil, but also some of the animal fats that hadn't previously been available to us. So we believe that environment will get better as we move into Q4; we see it improving as we move into Q4.

Rose Sparks executive
#12

Yes, that's a good point you brought up, and I'd add that starting 1/1/27 there will also be an equivalency factor advantage, since renewable diesel from our competitors will be treated as equivalent to our 1.5 D4 RIN, and that should help narrow the margin too. Timing is another piece of this. As we said on this call just a moment ago in our remarks, we had timing differences of $2.3 million related to our derivatives. So the physical gallons moving in Q4 will get a $2.3 million benefit, plus another $1.5 million from separated RIN sales. We produced those RINs in Q3, but they were sold for delivery in Q4.

Jeff Van Sinderen analyst
#13

All right, and I know you brought up visibility tied to some of those recent wins. Naturally, I'd expect a portion of the European reshoring to lend a hand there. Maybe just give us a bit of framing. I realize it's early, but when we look toward 2027, can we get some sense of how margins might develop in 2027?

Roeland Polet executive
#14

Sure. Yeah, I'd actually say Q3 was an unusual quarter, correct? So when you think about it, we had a turnaround that ran longer than we expected. Then came an inventory adjustment for what we refer to as customer A, and that represented roughly $4.3 million of EBITDA that we left there. In our view, that was atypical. Q4, we believe, is returning much more to a typical operating rate for our plant and more typical EBITDA generation. Then as we head into 2027, let me remind you of 2 things. First, we bought this — we constructed this large methacrylate plant that we operated this year at 50%, and next year we're going to operate it at probably closer to 70% capacity utilization, which is new capacity; and then the customer that took the inventory adjustment this year is the very same customer investing $41 million. Part of that is debottlenecking, which will come online next year; and then there's a significant step-up in production capabilities at the end of 2027 going into 2028. So it's the European onshoring. So we'll see more of that in terms of conversion out of the pipeline in 2027. But it's the actual investments we made last year and the investments being made right now, the customer funded investments, that are going to drive volume upside into 2027.

Roeland Polet executive
#15

Yes, and thanks a lot for joining the call. We really appreciate your interest in FutureFuel. We have strong conviction about this business. We firmly believe it is on an upward trajectory, and we look forward to having you with us on the next quarterly investment call. Thank you.

Operator operator
#16

Alright, everyone, that brings today's teleconference to a close. At this point you're free to disconnect your lines. Thanks so much for joining us, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete FutureFuel Corp. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to FutureFuel Corp. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.